Amicogen Balance Sheet Health
Financial Health criteria checks 1/6
Amicogen has a total shareholder equity of ₩214.2B and total debt of ₩180.0B, which brings its debt-to-equity ratio to 84%. Its total assets and total liabilities are ₩489.8B and ₩275.5B respectively.
Key information
84.0%
Debt to equity ratio
₩180.03b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩25.69b |
| Equity | ₩214.25b |
| Total liabilities | ₩275.52b |
| Total assets | ₩489.77b |
Recent financial health updates
Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?
Jun 19
Is Amicogen (KOSDAQ:092040) A Risky Investment?
Feb 15
Recent updates
Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding
Jun 27Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?
Jun 19Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%
Mar 21With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting
Mar 23Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?
Mar 05Is Amicogen (KOSDAQ:092040) A Risky Investment?
Feb 15What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?
Jan 31Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?
Jan 14Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?
Dec 30Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?
Dec 15Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?
Nov 30Financial Position Analysis
Short Term Liabilities: A092040's short term assets (₩152.4B) do not cover its short term liabilities (₩176.9B).
Long Term Liabilities: A092040's short term assets (₩152.4B) exceed its long term liabilities (₩98.6B).
Debt to Equity History and Analysis
Debt Level: A092040's net debt to equity ratio (72%) is considered high.
Reducing Debt: A092040's debt to equity ratio has increased from 22% to 84% over the past 5 years.
Debt Coverage: A092040's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if A092040's interest payments on its debt are well covered by EBIT.